MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

MDT

81.42

-1.31%↓

VEEV

208.52

-3.3%↓

A

99.74

-2.56%↓

WBA

10.84

-0.37%↓

CHE

558.79

-3.59%↓

Search

Codexis Inc

Open

SectorHealthcare

2.15 1.42

Overview

Share price change

24h

Current

Min

2.08

Max

2.23

Key metrics

By Trading Economics

Income

10M

-10M

Sales

8.6M

21M

EPS

-0.13

Profit margin

-48.35

Employees

188

EBITDA

3.8M

-9.9M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+216.11% upside

Dividends

By Dow Jones

Next Earnings

1 May 2025

Market Stats

By TradingEconomics

Market Cap

-36M

191M

Previous open

0.73

Previous close

2.15

News Sentiment

By Acuity

32%

68%

83 / 385 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Codexis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Apr 2025, 01:45 UTC

Earnings

Preview -- Barron's

18 Apr 2025, 15:57 UTC

Major Market Movers

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

20 Apr 2025, 22:32 UTC

Top News

Stocks Poised for Lower Open -- Barrons.com

20 Apr 2025, 18:43 UTC

Top News

Chicago Fed's Goolsbee Has a Warning About Independence -- Barrons.com

20 Apr 2025, 18:00 UTC

Top News

Tesla, Alphabet, Verizon, Chipotle, IBM, Boeing, and Many More Stocks to Watch This Week -- Barrons.com

20 Apr 2025, 13:00 UTC

Top News

Airbus Promised a Green Aircraft. That Bet Is Now Unraveling. -- WSJ

20 Apr 2025, 06:00 UTC

Top News

Foreign Stocks Are Beating the U.S. Market. Here's How Much You Should Have in Your Portfolio. -- Barrons.com

20 Apr 2025, 03:00 UTC

Top News

Putin's War Economy Can't Escape Trump's Trade Blitz -- WSJ

20 Apr 2025, 02:00 UTC

Top News

Who Will Pay the Price for Trump's Economic Goals? -- WSJ

19 Apr 2025, 02:00 UTC

Top News

Tomatoes Become One of the First Everyday Casualties of Trade War -- WSJ

19 Apr 2025, 02:00 UTC

Top News

Beijing Stokes Patriotic Fervor and Blames U.S. for Trade War -- WSJ

18 Apr 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 Apr 2025, 20:32 UTC

Top News

Trump to Replace Acting IRS Commissioner -- 2nd Update

18 Apr 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 Apr 2025, 19:52 UTC

Market Talk

Correction to Aluminum Fee Rising Slower Than Forecast Article

18 Apr 2025, 19:40 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

18 Apr 2025, 19:40 UTC

Market Talk

Aluminum Fee Rising Slower Than Forecast From Tariff -- Market Talk

18 Apr 2025, 18:51 UTC

Earnings

Netflix Has Made Several Risky Bets. Earnings Show They've Paid Off. -- Barrons.com

18 Apr 2025, 18:40 UTC

Acquisitions, Mergers, Takeovers

What Bill Ackman Sees in Hertz and Why He's Betting Big on the Rental-Car Company -- Barrons.com

18 Apr 2025, 18:29 UTC

Market Talk

Shorter Duration Seen as Way to Shield Portfolio From Political Turbulence -- Market Talk

18 Apr 2025, 18:21 UTC

Top News

Ford Halts Shipments of F-150s and Other Models to China -- WSJ

18 Apr 2025, 17:31 UTC

Top News

Trump to Replace Acting IRS Commissioner -- WSJ

18 Apr 2025, 17:24 UTC

Acquisitions, Mergers, Takeovers

Capital One's Discover Takeover Gets the Green Light. The Two Will Create the 6th-Largest U.S. Bank. -- Barrons.com

18 Apr 2025, 17:22 UTC

Acquisitions, Mergers, Takeovers

Capital One's $35 Billion Discover Takeover Clears Final Approvals -- Barrons.com

18 Apr 2025, 16:00 UTC

Top News

Trump's Trade War Threatens One of America's Top Energy Exports -- WSJ

18 Apr 2025, 15:53 UTC

Top News
Acquisitions, Mergers, Takeovers

Bill Ackman Teases Prospect of Uber, Hertz Partnership -- Update

18 Apr 2025, 15:46 UTC

Earnings

Tech's Problems in China Are Getting Worse. These Companies Are Most at Risk. -- Barrons.com

18 Apr 2025, 15:10 UTC

Market Talk
Earnings

Netflix Momentum Likely To Continue Thanks To Growing Subscriber Base -- Market Talk

18 Apr 2025, 14:46 UTC

Earnings

Tech Earnings Have Good News for Chip Stocks, So Far. And 1 Warning. -- Barrons.com

18 Apr 2025, 14:24 UTC

Market Talk
Earnings

Netflix Still Has Room to Add Subscribers -- Market Talk

Peer Comparison

Price change

Codexis Inc Forecast

Price Target

By TipRanks

216.11% upside

12 Months Forecast

Average 6.67 USD  216.11%

High 11 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forCodexis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

2.11 / 2.2508Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

83 / 385 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.